- Largest private financing round by an Asia-based life sciences tools company
- Important milestone in the development of Novo Holdings’ ambitions in Asia
- As a result of the financing, Amit Kakar, Senior Partner, Head of Novo Holdings Asia will join the company’s Board of Directors
Singapore & Copenhagen, Denmark, 27 May 2021 – Novo Holdings today announced that it has co-led with Vivo Capital the over-subscribed US$200 million Series A and Crossover round in Esco Lifesciences Group (“Esco”), a leading provider of life sciences tools and services. This is the largest private financing round by an Asia-based life sciences tools company. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and Singapore-based global investor, EDBI.